A Phase 3 interventional study of NTLA-2001 and Placebo in Transthyretin Amyloidosis (ATTR) With Cardiomyopathy, sponsored by Intellia Therapeutics. Recruiting at 138 sites in 26 countries. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2026-11-04.
Sponsored by Intellia Therapeutics · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 37 studies in Amyloidosis, Hereditary, Transthyretin-Related with a site in United States — 10 open to participants now, 12 under way, 4 of them phase 3. Amyloidosis, Hereditary, Transthyretin-Related · United States.
Among the 37 studies in Amyloidosis, Hereditary, Transthyretin-Related with a site in United States, this one has the largest planned enrollment of the 23 interventional ones that give a count, is one of 5 that started in 2023, is one of 10 in phase 3, reaches primary completion later than 4 of the 11 other live ones, and was the 31st registered.
82 studies on the registry are indexed under Amyloidosis, Hereditary, Transthyretin-Related; 28 are open to participants now.
Browse Amyloidosis, Hereditary, Transthyretin-Related studies →10 of the 37 studies in Amyloidosis, Hereditary, Transthyretin-Related with a site in United States are open now. Recruiting first, the newest first:
AstraZeneca · Sites in United States, Canada, China and 3 more countries
Ages 18+
Eidos Therapeutics, a BridgeBio company · Sites in United States, Singapore, Spain
Ages 18–80
Eidos Therapeutics, a BridgeBio company · Sites in United States, Argentina, Australia and 21 more countries
Ages 18–75
AstraZeneca · Sites in United States, Canada, China and 3 more countries
Ages 18–130
Oregon Health and Science University · Sites in United States
Ages 40–90
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 22 Amyloidosis, Hereditary, Transthyretin-Related studies recruiting now, 15 (68%) set no upper age limit and 1 (5%) stops at 75 or younger; 2 take children under 18; 4 take healthy volunteers.
This study: 18 Years to 90 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
37 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 3 · Phase 3 10 · Phase 4 3
First in 2008; this study’s year is marked. 5 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 1,200 is above the median of 80 across 36 interventional studies indexed under Amyloidosis, Hereditary, Transthyretin-Related.
Median enrollment 150 across the 23 interventional studies, 119 across the 14 observational. Of the 22 that completed or were terminated, 10 (45%) have results posted.
This tab as a report to print or save as PDF → With an account.
20 of 37 have an industry lead sponsor. The 10 most frequent:
Intellia Therapeutics is the lead sponsor of 9 studies on the registry; 3 are open to participants now.
Intellia Therapeutics has 2 studies filed under Amyloidosis, Hereditary, Transthyretin-Related — fewer than ten, so there is no comparison to draw.
2 of the studies in Amyloidosis, Hereditary, Transthyretin-Related with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05489523University of Texas Southwestern Medical CenterSafety, Efficacy, and Pharmacokinetics of Tafamidis in Patients With Transthyretin-mediated Amyloidosis Post Orthotopic Heart Transplantation | 2027-05-31 |
| NCT05489549University of Texas Southwestern Medical CenterSubclinical Transthyretin Cardiac Amyloidosis in V122I TTR Carriers | 2027-06-30 |
Add all 2 to your calendar (.ics) → With an account.
Among the 37 studies in Amyloidosis, Hereditary, Transthyretin-Related with a site in United States, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
To evaluate the efficacy and safety of a single dose of NTLA-2001 compared to placebo in participants with ATTR-CM.
This is a multinational, multicenter, double-blind, placebo-controlled study in approximately 1200 participants, who will be randomized to receive a single infusion of either NTLA-2001 or placebo.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Single intravenous (IV) infusion of NTLA-2001
Biological: NTLA-2001
Single IV infusion of normal saline
Drug: Placebo
NTLA-2001 (55mg) by IV infusion
Normal saline (0.9% NaCl) by IV infusion
Composite outcome of cardiovascular (CV) mortality and CV events
Time frame: Maximum study duration is dependent on event rates and is estimated to be at least 18 months and up to approximately 5 years
Change in baseline to month 18 in serum TTR
Time frame: Baseline, Month 18
Change from baseline to month 18 in KCCQ-OS score
Time frame: Baseline, Month 18
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Showing the first 100 of 138 sites across 26 countries. Choose a country and city above to see the rest.
Plan to share: No
No publications or documents are linked to this record.
Started Dec 2023 (actual). Primary completion is estimated for Dec 2027, 48 months after the start.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: NTLA-2001
Amyloidosis, Hereditary, Transthyretin-Related →
Intellia Therapeutics